Paraquat lawsuit update

Verified snapshot

The facts that anchor this dossier

MDL 3004 has moved from expert exclusions and bellwether dismissals into a settlement process, but the public docket still does not provide a universal eligibility rule or payout schedule.

Federal proceeding

MDL 3004

Coordinated in the Southern District of Illinois before Judge Nancy J. Rosenstengel.

Pending actions

6,665

JPML count as of July 1, 2026; 8,484 historical actions.

Settlement status

Court-supervised process underway

Orders in 2025 and 2026 discuss an agreement in principle, a stay, a special master and opt-out discovery. Public materials do not reveal a general award matrix.

Core allegation

Paraquat exposure and Parkinson's disease

Plaintiffs allege a causal relationship; defendants dispute it, and the scientific literature is not uniform.

EPA position

No clear link found from labeled uses

EPA says it reviewed conflicting evidence and has not found a clear link between labeled paraquat uses and Parkinson's disease or cancer.

Documented chronology

How the litigation reached this point

The dispute in plain English

Paraquat is a highly toxic herbicide used in agricultural and some non-agricultural settings. Federal plaintiffs generally allege that occupational, direct or nearby exposure contributed to Parkinson's disease and that manufacturers and sellers failed to provide adequate warnings. The defendants dispute liability and causation. MDL 3004 centralizes common pretrial questions; it does not establish that paraquat caused every plaintiff's diagnosis.

EPA classifies all U.S.-registered paraquat products as restricted-use pesticides. Only trained certified applicators may use them, and EPA says there are no homeowner or residential-area uses. Acute poisoning is a separate medical emergency: EPA warns that one small sip can be fatal and that no antidote exists. The MDL's Parkinson's allegations concern a different question—whether particular patterns of longer-term exposure can be proven to cause a neurodegenerative disease in a given person.

Why the science cannot be reduced to one slogan

The research record contains competing signals. A 2019 systematic review and meta-analysis of observational studies reported a positive association overall but concluded that the weight of evidence did not permit an indisputable cause-and-effect conclusion. A 2024 California case-control study associated estimated residential and workplace proximity to agricultural paraquat application with Parkinson's disease, including stronger estimates for longer workplace proximity.

EPA reaches a more cautious regulatory conclusion. Its current paraquat page says studies vary in quality and conflict, notes that an updated Agricultural Health Study analysis did not reproduce an earlier association, and says the agency has not found a clear link between exposure from labeled uses and Parkinson's disease or cancer. NIEHS, meanwhile, summarizes funded research connecting several pesticides, including paraquat, with Parkinson's onset and progression. A fair account presents these positions together and avoids treating any one study as an individual diagnosis.

What happened to the first bellwether cases

Expert evidence became decisive. The MDL court later explained that the first bellwether cases did not survive a Daubert challenge and were dismissed in April 2024. Daubert rulings ask whether proposed expert testimony is sufficiently reliable and helpful under the rules of evidence. They are not the same as a scientific agency banning a product, nor do they automatically dispose of every future case with different experts or evidence.

A second set of cases entered case-specific discovery. The court then stayed deadlines in May 2025 while the parties worked on a global settlement said to have been agreed in principle. In September 2025 it extended the stay and vacated the approaching trial date so the settlement process could unfold. The court's public chronology therefore shows both litigation risk and negotiated resolution activity—without exposing the private variables used to assess individual claims.

What the 2026 settlement orders do and do not establish

The court continued managing dismissals, the settlement process and cases outside it during 2026. Order No. 24 gave the special master access to settlement information. June orders selected opt-out cases from identified law firms for limited discovery, and the court adopted a special-master recommendation. Those steps show that an organized process is active and that not every procedural path is identical.

They do not publish a universal Parkinson's diagnosis date, exposure minimum, deadline or dollar schedule. “Global settlement” in an order is not synonymous with an automatic payment to everyone who ever handled paraquat. Participation may depend on representation, proof, filing posture, releases and agreement-specific rules. Some people or firms may opt out. Any statement about a particular person's eligibility must come from the controlling documents and counsel, not a generic online calculator.

Building a reliable exposure and medical chronology

Useful evidence may include pesticide applicator licenses, employer and farm records, product purchase invoices, spray logs, crop and acreage histories, co-worker testimony, personal protective equipment practices and addresses near application sites. Labels and formulations can change over time, so the approximate year, task, frequency and method of use matter. Simply having worked in agriculture does not identify paraquat exposure.

Medical records should establish the diagnostic pathway, symptoms, neurologic examinations, alternative diagnoses and relevant family and occupational history. A Parkinson's diagnosis is medically significant but does not identify a cause. Timing can also affect legal rights under state-specific limitation and repose rules. People worried about present exposure or poisoning should contact medical or poison-control professionals immediately; litigation research is not emergency guidance.

Reader questions

Frequently asked questions